Shandong Provincial Public Resource Trading Center issued the "Shandong Province's Third Batch of Drugs (Special Chinese Patent Medicines) Centralized Procurement Documents (Draft for Comment)"

01

010101

Special centralized procurement of Chinese patent medicines, documents released

Special centralized procurement of Chinese patent medicines, documents released

On August 4, the Shandong Provincial Public Resource Trading Center released the "Shandong Province Third Batch of Drugs (Special Chinese Patent Medicines) Centralized Procurement Documents (Draft for Comments)", which will be publicized from August 5 to 9, 2022

This special collection of proprietary Chinese medicines covers a total of 15 varieties of 67 drugs, including Xuesaitong, Xueshuantong, Bailing, Zhiling, Jinshuibao, Ginkgo biloba, Xuefuzhuyu, Huoxuezhitong, Cinobufasu, Shuxue Ning, Kangfuxin, Fufang Xueshuantong, Jianweixiaoshi, Jiegu Qili, Shenmai, Ginkgo ketone ester, Xingling, Xiaojin and other products

The whole is mainly oral Chinese patent medicine, and the injection formulations are only four types: Shuxuetong for injection, Xuesaitong for injection, Shuxuening injection, and Shenmai injection—including Shuxuening injection, Shenmai injection, and Kangfuxin.

In this round of special Chinese patent medicine collection in Shandong, there are many varieties that overlap with the collection of Chinese patent medicines from 19 provinces such as Hubei.

Indeed, in the centralized procurement notice issued by Beijing on July 29, many varieties of the Hubei 19-province alliance and the Guangdong 6-province alliance have appeared - Chinese patent medicines with sufficient competition in volume: Bailing, Xiaojin, Ginkgo biloba, Xuesai Tong, Xueshuantong, Xuefu Zhuyu, Shuxuening, Kangfuxin, Shengmai, etc.

According to the previous notification of the medical insurance bureau of a city in Shandong Province, the report of the special centralized procurement of Chinese patent medicines in Shandong has been considered to be over

With the confirmation of the special centralized procurement documents for Chinese patent medicines in Shandong, the bid opening time is expected to surface - Shandong may also become the first province in the country to independently carry out the special centralized procurement of Chinese patent medicines

With the confirmation of the special centralized procurement documents for Chinese patent medicines in Shandong, the bid opening time is expected to surface - Shandong may also become the first province in the country to independently carry out the special centralized procurement of Chinese patent medicines

02

020202

Group bidding, comprehensive review

Group bidding, comprehensive review group bidding, comprehensive review group bidding, comprehensive review

According to Cyberland’s observation, the plans put forward by the special centralized procurement of Chinese patent medicines in Shandong include the alliance of 19 provinces including Hubei, the alliance of 6 provinces including Guangdong, and even some experience in the state’s organization of centralized drug procurement
.

According to Cyberland’s observation, the plans put forward by the special centralized procurement of Chinese patent medicines in Shandong include the alliance of 19 provinces including Hubei, the alliance of 6 provinces including Guangdong, and even some experience in the state’s organization of centralized drug procurement
.

First of all, Shandong also groups the declared companies according to the market occupancy rate.
Generally speaking, companies with a large market share enter the first review group
.

First of all, Shandong also groups the declared companies according to the market occupancy rate.
Generally speaking, companies with a large market share enter the first review group
.

The document clarifies that, based on the average daily dosage, the total number of days of taking the same variety and the same enterprise is converted into two evaluation groups:

The document clarifies that, based on the average daily dosage, the total number of days of taking the same variety and the same enterprise is converted into two evaluation groups:

The first review group: According to the total number of days of use of each online product of the applicant enterprise, the proportion of the applicant enterprises from high to low has reached 80%
.
If the number of companies is less than 3, 3 companies will be added in descending order of the proportion of the total number of days of use
.

The first review group: According to the total number of days of use of each online product of the applicant enterprise, the proportion of the applicant enterprises from high to low has reached 80%
.
If the number of companies is less than 3, 3 companies will be added in descending order of the proportion of the total number of days of use
.

The second review group: other applicants except the first review group
.
If the number of enterprises is less than 3, all the declared enterprises will be incorporated into the first evaluation group, and the second evaluation group will not be set up
.

The second review group: other applicants except the first review group
.
If the number of enterprises is less than 3, all the declared enterprises will be incorporated into the first evaluation group, and the second evaluation group will not be set up
.

Secondly, Shandong's highest effective declared price abandoned the method of the lowest online price adopted by some provinces, and proposed the concept of daily average cost
.
Some experts pointed out that this move is aimed at bridging the price gap between the declared enterprises and adjusting the widely discussed before, because different enterprises have different maximum effective declaration prices for the same group of varieties, so when only looking at the decline, the high quotation is regarded as a large decline.
situation
.

Secondly, Shandong's highest effective declared price abandoned the method of the lowest online price adopted by some provinces, and proposed the concept of daily average cost
.
Some experts pointed out that this move is aimed at bridging the price gap between the declared enterprises and adjusting the widely discussed before, because different enterprises have different maximum effective declaration prices for the same group of varieties, so when only looking at the decline, the high quotation is regarded as a large decline.
situation
.

The document proposes that, according to the daily average cost and transaction quantity of all the declared enterprises of the same product listed on the Internet, the daily average cost of the product should be weighted and calculated as the highest effective declared price unified by the first and second review groups of the product
.

The document proposes that, according to the daily average cost and transaction quantity of all the declared enterprises of the same product listed on the Internet, the daily average cost of the product should be weighted and calculated as the highest effective declared price unified by the first and second review groups of the product
.

Of course, this attempt also reflects to a certain extent that Shandong may continue the centralized procurement strategy of Chinese patent medicines with moderate price reduction
.

Of course, this attempt also reflects to a certain extent that Shandong may continue the centralized procurement strategy of Chinese patent medicines with moderate price reduction
.

Third, the applicant enterprise shall use the product with the largest total number of days in the review group (mainly those with a high market share) as the representative product, and use the daily average cost as the declared price—the declared price shall not be higher than the average daily cost of the representative product, The lower of the two highest valid quotations, otherwise it is an invalid quotation
.

Third, the applicant enterprise shall use the product with the largest total number of days in the review group (mainly those with a high market share) as the representative product, and use the daily average cost as the declared price—the declared price shall not be higher than the average daily cost of the representative product, The lower of the two highest valid quotations, otherwise it is an invalid quotation
.

Fourth, the document clarifies that Shandong still adopts a comprehensive review method to generate the selected companies - comprehensively paying attention to factors such as the declared price of the company's representative products, the proportion of the total number of days that the company's products are used, and the product quality and safety
.

Fourth, the document clarifies that Shandong still adopts a comprehensive review method to generate the selected companies - comprehensively paying attention to factors such as the declared price of the company's representative products, the proportion of the total number of days that the company's products are used, and the product quality and safety
.

In general, the lower the declared price is in terms of quotation, the more the company has scored, and the quotation score accounts for 60%; the market share score accounts for 40%.
For the same variety, the greater the market share, the higher the score.
High; no points are added for product quality, only points are subtracted—emphasis is placed on focusing on product production
.

In general, the lower the declared price is in terms of quotation, the more the company has scored, and the quotation score accounts for 60%; the market share score accounts for 40%.
For the same variety, the greater the market share, the higher the score.
High; no points are added for product quality, only points are subtracted—emphasis is placed on focusing on product production
.

Price reduction, market share, and product quality control are the selection criteria for Shandong's current round of special centralized procurement of proprietary Chinese medicines
.

Price reduction, market share, and product quality control are the selection criteria for Shandong's current round of special centralized procurement of proprietary Chinese medicines
.

03

030303

The dropout rate is not high, but the uncertainty of the weight is large

The out rate is not high, but the component uncertainty is large The out rate is not high, but the component uncertainty is large The out rate is not high, but the component uncertainty is large

According to the draft regulations, the number of shortlisted companies is at most 5.
When the number of validly declared companies is 6 or less, the selection rate of companies is relatively large.
Only when the number of validly declared companies is greater than or equal to 7, the shortlist competition will heat up significantly.

.

According to the draft regulations, the number of shortlisted companies is at most 5.
When the number of validly declared companies is 6 or less, the selection rate of companies is relatively large.
Only when the number of validly declared companies is greater than or equal to 7, the shortlist competition will heat up significantly.

.

According to the order of enterprise comprehensive evaluation score from high to low, the shortlisted enterprises of the evaluation group are determined
.
When the comprehensive evaluation scores are the same, the short-listed enterprises will be determined by comparing the following conditions in order: ① the enterprises with lower declared prices are preferred; ② the enterprises with a higher proportion of the total number of days in which their products are used are preferred
.

According to the order of enterprise comprehensive evaluation score from high to low, the shortlisted enterprises of the evaluation group are determined
.
When the comprehensive evaluation scores are the same, the short-listed enterprises will be determined by comparing the following conditions in order: ① the enterprises with lower declared prices are preferred; ② the enterprises with a higher proportion of the total number of days in which their products are used are preferred
.

From the shortlisted company to the proposed company, one of the following conditions must also be met:

From the shortlisted company to the proposed company, one of the following conditions must also be met:

①The declared price of the shortlisted enterprises in the same evaluation group is not the highest declared price
.

①The declared price of the shortlisted enterprises in the same evaluation group is not the highest declared price
.

② The shortlisted enterprises with the highest declared price in the same evaluation group shall calculate the ratio according to "the highest declared price of the shortlisted enterprises in the same evaluation group / the lowest declared price of the shortlisted enterprises in the same evaluation group", and its ratio is ranked in descending order of the ratio of all evaluation groups in this centralized procurement.
2 of them
.
If the calculated ratio with the 2nd place is equal, then the tie for the 2nd place
.

② The shortlisted enterprises with the highest declared price in the same evaluation group shall calculate the ratio according to "the highest declared price of the shortlisted enterprises in the same evaluation group / the lowest declared price of the shortlisted enterprises in the same evaluation group", and its ratio is ranked in descending order of the ratio of all evaluation groups in this centralized procurement.
2 of them
.
If the calculated ratio with the 2nd place is equal, then the tie for the 2nd place
.

These two regulations are logically consistent with the conditions for the selection of leverage for the seventh batch of newly-added pharmaceutical companies in China.
They both focus on high quoted prices and pay attention to the price difference between quotations from the same approval group, creating price reporting pressure on high-quoting companies
.

These two regulations are logically consistent with the conditions for the selection of leverage for the seventh batch of newly-added pharmaceutical companies in China.
They both focus on high quoted prices and pay attention to the price difference between quotations from the same approval group, creating price reporting pressure on high-quoting companies
.

For companies with high quotations, Shandong’s current round of centralized procurement of proprietary Chinese medicines has also given additional opportunities to be selected – the top 2 companies ranked in descending order by the ratio of all the evaluation groups among the shortlisted companies will accept the average declared price of the companies to be selected by the same evaluation group, and the supplement will be as follows: The company to be selected
.

For companies with high quotations, Shandong’s current round of centralized procurement of proprietary Chinese medicines has also given additional opportunities to be selected – the top 2 companies ranked in descending order by the ratio of all the evaluation groups among the shortlisted companies will accept the average declared price of the companies to be selected by the same evaluation group, and the supplement will be as follows: The company to be selected
.

In addition, for companies that are not shortlisted and validly declared, whose products account for more than 30% of the total days of use, and accept the lowest declared price of the companies to be selected by the same review group, they will be added to the companies to be selected.
For companies with a large market share, the rules Still tend to respect the hospital's original clinical medication habits
.

In addition, for companies that are not shortlisted and validly declared, whose products account for more than 30% of the total days of use, and accept the lowest declared price of the companies to be selected by the same review group, they will be added to the companies to be selected.
For companies with a large market share, the rules Still tend to respect the hospital's original clinical medication habits
.

The special centralized procurement of Chinese patent medicines in Shandong, like the seventh batch of national procurement, also proposed a mechanism for alternative enterprises
.

The special centralized procurement of Chinese patent medicines in Shandong, like the seventh batch of national procurement, also proposed a mechanism for alternative enterprises
.

Valid declaration companies that are not shortlisted, if they are selected enterprises for centralized procurement from other provinces, whose declared price is 10% or more lower than the selected price for centralized procurement from other provinces, and not higher than the highest valid declared price and the Shandong Province platform listing price, are determined to be reserved.
Selecting a company - the company is willing to make another cut before it can obtain the candidate qualifications in Shandong Province, which is not easy
.

Valid declaration companies that are not shortlisted, if they are selected enterprises for centralized procurement from other provinces, whose declared price is 10% or more lower than the selected price for centralized procurement from other provinces, and not higher than the highest valid declared price and the Shandong Province platform listing price, are determined to be reserved.
Selecting a company - the company is willing to make another cut before it can obtain the candidate qualifications in Shandong Province, which is not easy
.

Shandong further clearly stipulates that the price to be selected for representative and non-representative products shall not be higher than the original online price of the product and the price selected for centralized procurement in other provinces
.

Shandong further clearly stipulates that the price to be selected for representative and non-representative products shall not be higher than the original online price of the product and the price selected for centralized procurement in other provinces
.

Finally, the agreed procurement volume allocation:

Finally, the agreed procurement volume allocation:

If the product for which the pharmaceutical institution fills in the purchase demand is in the selected range, 80% of its purchase demand will be allocated to the product, and the allocation ratio of the product purchase demand of the supplementary enterprise to be selected will be 40%
.

If the product for which the pharmaceutical institution fills in the purchase demand is in the selected range, 80% of its purchase demand will be allocated to the product, and the allocation ratio of the product purchase demand of the supplementary enterprise to be selected will be 40%
.

The amount to be allocated consists of two parts: one is 80% of the product purchase demand of the unselected enterprises (including undeclared enterprises and alternative enterprises); the other is 40% of the product purchase demand of the proposed selected enterprise
.
The amount to be allocated shall be freely allocated by the pharmaceutical institutions among the selected enterprises in the two evaluation groups of the same variety, and the pharmaceutical institutions are encouraged to give priority to the selected products with lower prices
.

The amount to be allocated consists of two parts: one is 80% of the product purchase demand of the unselected enterprises (including undeclared enterprises and alternative enterprises); the other is 40% of the product purchase demand of the proposed selected enterprise
.
The amount to be allocated shall be freely allocated by the pharmaceutical institutions among the selected enterprises in the two evaluation groups of the same variety, and the pharmaceutical institutions are encouraged to give priority to the selected products with lower prices
.

According to the draft for comments, Shandong will announce the results of the election after there is no objection to the announcement
.
The selected price of the medicines generated by the special centralized procurement of Chinese patent medicines in this round is limited to the use of medicines purchased by pharmaceutical institutions in Shandong Province in volume, and is not used for other purposes
.

According to the draft for comments, Shandong will announce the results of the election after there is no objection to the announcement
.
The selected price of the medicines generated by the special centralized procurement of Chinese patent medicines in this round is limited to the use of medicines purchased by pharmaceutical institutions in Shandong Province in volume, and is not used for other purposes
.

Up to now, 19 provinces including Hubei, 6 provinces including Guangdong, Beijing and Shandong have clearly carried out centralized procurement of Chinese patent medicines, and Anhui and Tianjin have also made centralized procurement of traditional Chinese medicines as one of their work plans
.

Up to now, 19 provinces including Hubei, 6 provinces including Guangdong, Beijing and Shandong have clearly carried out centralized procurement of Chinese patent medicines, and Anhui and Tianjin have also made centralized procurement of traditional Chinese medicines as one of their work plans
.

According to the unified deployment and coordination of the National Medical Insurance Bureau for the centralized procurement of local alliances, the centralized procurement of Chinese patent medicines to be promoted in 2022 includes: Hubei will lead the procurement of Chinese patent medicine alliances; The cumulative number of drug varieties for centralized procurement shall be no less than 100, and shall include Chinese patent medicines
.

According to the unified deployment and coordination of the National Medical Insurance Bureau for the centralized procurement of local alliances, the centralized procurement of Chinese patent medicines to be promoted in 2022 includes: Hubei will lead the procurement of Chinese patent medicine alliances; The cumulative number of drug varieties for centralized procurement shall be no less than 100, and shall include Chinese patent medicines
.

The traditional Chinese medicine commonly used in the hospital has entered the price reduction cycle in turn, and it is expected to be in the near future
.

The traditional Chinese medicine commonly used in the hospital has entered the price reduction cycle in turn, and it is expected to be in the near future
.

Attachment: Catalogue of special collection varieties of Chinese patent medicines in Shandong

Attachment: Catalogue of special collection varieties of Shandong Chinese patent medicines Attached: Catalogue of special collection varieties of Shandong Chinese patent medicines Attached: Catalogue of special collection varieties of Shandong Chinese patent medicines

Attachment: Catalogue of Beijing Chinese Patent Medicines with Volume-Linked Drugs

Attachment: Catalogue of Beijing Chinese Patent Medicines with Volume-Linked Drugs Attached: Beijing Chinese Patent Medicines Volume-linked Drug Catalog Attached: Beijing Chinese Patent Medicines Volume-linked Drug Catalogue

Attachment: Beijing Catalogue of Negotiated Drugs with Volume

Attachment: Catalogue of drugs negotiated with quantity in Beijing Attached: Catalogue of drugs negotiated with quantity in Beijing Attached: Catalogue of drugs negotiated with quantity in Beijing